Angiotensin-Converting Enzyme Inhibitors

"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Descriptor ID	D000806
MeSH Number(s)	D27.505.519.389.745.085
Concept/Terms	Angiotensin-Converting Enzyme Inhibitors Angiotensin-Converting Enzyme Inhibitors Angiotensin Converting Enzyme Inhibitors Inhibitors, Kininase II Kininase II Antagonists Kininase II Inhibitors Angiotensin I-Converting Enzyme Inhibitors Angiotensin I Converting Enzyme Inhibitors Antagonists, Angiotensin-Converting Enzyme Antagonists, Angiotensin Converting Enzyme Antagonists, Kininase II Inhibitors, ACE ACE Inhibitors Inhibitors, Angiotensin-Converting Enzyme Enzyme Inhibitors, Angiotensin-Converting Inhibitors, Angiotensin Converting Enzyme Angiotensin-Converting Enzyme Antagonists Angiotensin Converting Enzyme Antagonists Enzyme Antagonists, Angiotensin-Converting

Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
Angiotensin-Converting Enzyme Inhibitors [D27.505.519.389.745.085]

Below are MeSH descriptors whose meaning is related to "Angiotensin-Converting Enzyme Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".

Angiotensin-Converting Enzyme Inhibitors
Vasopeptidase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.

Bar chart showing 167 publications over 29 distinct years, with a maximum of 14 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	1	1	2
1995	1	1	2
1996	2	2	4
1997	2	0	2
1998	1	1	2
1999	3	1	4
2000	0	5	5
2001	3	2	5
2002	7	4	11
2003	3	2	5
2004	1	2	3
2005	0	3	3
2006	2	3	5
2007	3	3	6
2008	6	5	11
2009	3	1	4
2010	1	6	7
2011	1	4	5
2012	3	0	3
2013	3	2	5
2014	2	6	8
2015	5	6	11
2016	10	4	14
2017	3	3	6
2018	4	5	9
2019	4	7	11
2020	1	5	6
2021	2	4	6
2022	0	2	2

Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.

Masarone D, Tedford RJ, Melillo E, Petraio A, Pacileo G. Angiotensin-converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects. Clin Transplant. 2022 07; 36(7):e14696.

View in: PubMed
Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, Jhund PS, McGrath MM, Rouleau JL, Shi V, Swedberg K, Vaduganathan M, Zannad F, Pfeffer MA, Zile M, McMurray JJV, Solomon SD. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 Sep; 24(9):1591-1598.

View in: PubMed
Daoud A, Ali H, Rao V, Rohan V, Soliman K. ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients. Ren Fail. 2021 12; 43(1):1463-1464.

View in: PubMed
Egan BM, Yang J, Rakotz MK, Sutherland SE, Jamerson KA, Wright JT, Ferdinand KC, Wozniak GD. Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension. 2022 02; 79(2):338-348.

View in: PubMed
Shen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP, Martinez FA, Pfeffer MA, Rizkala AR, Rouleau JL, Swedberg K, Vaduganathan M, Vardeny O, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Solomon SD, McMurray JJV. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 04 27; 77(16):1961-1973.

View in: PubMed
Rohde LE, Claggett BL, Wolsk E, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer MA, Desai AS, Lund LH, Kober L, Anand I, Merkely B, Senni M, Shi V, Rizkala A, Lefkowitz M, McMurray JJV, Solomon SD. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.

View in: PubMed
Tran JS, Havakuk O, McLeod JM, Hwang J, Kwong HY, Shavelle D, Zile MR, Elkayam U, Fong MW, Grazette LP. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail. 2021 04; 8(2):1706-1710.

View in: PubMed
Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.

View in: PubMed
Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, Anand IS, van Veldhuisen DJ, Kober L, Janssens S, Cleland JGF, Pieske B, Rouleau JL, Zile MR, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020 11; 22(11):2093-2101.

View in: PubMed
Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR, Rossignol P, Zannad F, Packer M, Solomon SD, McMurray JJV. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.

View in: PubMed

People

Explore

Similar Concepts

Top Journals